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Expression of virulence determinants by Bordetella pertussis, the primary etiological agent of whooping cough,
is regulated by the BvgAS two-component regulatory system. The role of a second two-component regulatory
system, encoded by risAS, in this process is not defined. Here, we show that mutation of B. pertussis risA does
not affect Bvg-activated genes or proteins. However, mutation of risA resulted in greatly diminished expression
of Bvg-repressed antigens and decreased transcription of Bvg-repressed genes. In contrast, mutation of risS
had no effect on the expression of Bvg-regulated molecules. Mutation of risA also resulted in decreased
bacterial invasion in a HeLa cell model. However, decreased invasion could not be attributed to the decreased
expression of Bvg-repressed products, suggesting that mutation of risA may affect the expression of a variety
of genes. Unlike the risAS operons in B. parapertussis and B. bronchiseptica, B. pertussis risS is a pseudogene that
encodes a truncated RisS sensor. Deletion of the intact part of the B. pertussis risS gene does not affect the
expression of risA-dependent, Bvg-repressed genes. These observations suggest that RisA activation occurs
through cross-regulation by a heterologous system.
Bordetellae are gram-negative coccobacilli that cause respi-
ratory diseases in several host species. These include whooping
cough in humans, caused by Bordetella pertussis and human
strains of B. parapertussis. B. pertussis, B. parapertussis, and B.
bronchiseptica are closely related and are considered to be
subspecies within the B. bronchiseptica cluster (4, 24, 49, 63). In
particular, B. pertussis and B. parapertussis appear to have
evolved independently from a progenitor bacterium most sim-
ilar to B. bronchiseptica through selective gene loss and inac-
tivation (14, 49). These subspecies share many similarities but
possess interesting differences, which are likely to account for
their different host specificities and abilities to cause disease
(27, 28). One clear similarity is the presence in all of these
three bordetellae of the BvgAS two-component regulatory sys-
tem, encoded by the bvg locus (for Bordetella virulence gene),
which controls the expression of virulence determinants in all
three subspecies (36, 53).
BvgAS is a member of the large family of two-component
response regulators. These are comprised of a sensor protein
(that is generally transmembrane) and a cytoplasmic transcrip-
tional regulator protein. These systems respond to environ-
mental signals and regulate target gene transcription (46). Spe-
cifically, the BvgS sensor can respond to signals such as
temperature and high concentrations of -vitamin derivatives
(e.g., nicotinic acid) and sulfate anions (34, 40). Under per-
missive conditions, such as growth at 37°C in low sulfate and
nicotinic acid concentrations, BvgS initiates a complex phos-
phorelay cascade that ultimately results in phosphorylation of
BvgA (62). Phosphorylated BvgA then acts as a transcriptional
activator at cis-acting sites for a number of genes known as
Bvg-activated genes, or vags (52). An additional level of regu-
latory complexity is evident in that the vags can be separated
into early- and late-activated genes whose temporal expression
differs when the bacteria are switched between conditions (32,
54). When Bordetella spp. are grown in vitro at low tempera-
tures or in the presence of high sulfate or nicotinic acid con-
centrations, the BvgAS system is inactive: there are low levels
of phosphorylated BvgA transactivator, resulting in low, basal,
or virtually absent transcription of the individual vags and low
expression of their encoded virulence factors. This process has
been called antigenic or phenotypic modulation, and the chem-
icals that induce it are called modulators (34, 40). Modulation
also results in the up-regulation of the expression of another
set of genes, known as Bvg-repressed genes, or vrgs (33).
The vags include the bvgAS locus itself (51), bvgR encoding
a transcriptional repressor (41), and a broad set of other genes
(9, 25, 35, 38, 50). The vag-encoded products include the ma-
jority of known virulence factors of these pathogens and are
shared mostly between B. pertussis, B. parapertussis, and B.
bronchiseptica. Notable exceptions include pertussis toxin,
which is believed to be expressed only in B. pertussis (5); PagP,
which is apparently not expressed in B. pertussis (50); and the
Bcr type III secretion system, which, despite being transcrip-
tionally active in B. pertussis, is nonfunctional (29, 38).
In contrast, the vrgs encode factors whose expression is more
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divergent between the broad-host-range pathogen B. bronchi-
septica and the obligate human pathogen B. pertussis (14, 49).
Their products include B. bronchiseptica-specific flagella (2)
and urease (39) and B. pertussis-specific vrgs and antigens
(Vras) with unknown functions (3, 29, 33, 57). The repression
of the vrgs appears to be mediated principally through the
vag-encoded transcriptional repressor BvgR, which is believed
to bind at cis-repressive sites of the vrg genes (7, 41, 42). The
expression of the vrgs is maximal late in the bacterial growth
phase (55), and individual vrgs are differentially modulated by
individual in vitro modulators (29). In addition to the vags and
the vrgs, there is a third gene class, Bvg-intermediate, exem-
plified by the bipA gene (60) whose transcription is maximal at
semimodulating conditions (16).
A second two-component regulatory system, RisAS, has
been described and analyzed in B. bronchiseptica (30, 65). This
system is related to the EnvZ-OmpR systems of other gram-
negative bacteria including Escherichia coli, Salmonella enterica
serovar Typhimurium, and Shigella flexneri (22) that recipro-
cally regulate the expression of porins OmpC and OmpF in
response to osmolarity. Interestingly, they are also implicated
in bacterial virulence. For example, Xenorhabdus nematophilus
envZ mutants have decreased the production of a number of
outer membrane proteins and are less pathogenic in host to-
bacco worms (23), S. enterica serovar Typhimurium ompR mu-
tants are less virulent in mice (18), ompR is required for Yer-
sinia enterocolitica survival in macrophages (10), and both
ompR and envZ mutants of S. flexneri are less able to invade
HeLa cells (8).
The RisAS system is considered to be an ortholog, not a
homolog, of OmpR/EnvZ, as it does not respond to osmolarity
as an environmental signal and apparently does not regulate
the expression of porins in B. bronchiseptica (30). Rather,
RisAS coordinately regulates a variety of factors, acting inde-
pendently of Bvg-mediated regulation. Furthermore, Ris ex-
pression is induced when B. bronchiseptica is intracellular and
is required for intracellular survival, resistance to oxidative
stress, and persistence in a mouse infection model (30, 65).
This implicates Ris as a second two-component regulatory
system important in the pathogenesis of the bordetellae.
In this study, we describe a comprehensive analysis of the
RisAS system in B. pertussis and show that risA affects the
transcription and expression of vrgs but not the vags, whereas
risS does not affect vrg or vag expression probably because it is
a pseudogene in B. pertussis. risA mutants adhere just as well as
wild-type bacteria but are less efficient at invasion of HeLa
cells, indicating a role in the host-pathogen relationship for this
system. RisA can function independent of RisS, suggesting the
possibility of cross talk between regulatory systems and the
integration of multiple regulatory signals in the expression of
Bvg-regulated molecules in B. pertussis.
MATERIALS AND METHODS
Bacterial strains and plasmids. The strains and plasmids used in this study are
listed in Table 1. Bordetella pertussis strains were grown on Bordet-Gengou agar
(BGA; Difco, Detroit, MI) containing 15% sheep’s blood (Dalynn, Calgary,
Alberta, Canada) for 3 days at 37°C in a humidified atmosphere prior to exper-
imental assays, unless otherwise noted. To induce modulation, B. pertussis strains
were grown on BGA containing 5 mM nicotinic acid and 40 mM MgSO4 (7, 25).
E. coli strains were grown in L broth or on L agar. When necessary, the following
antibiotics at the indicated concentrations were added to the media: nalidixic
acid, 30 g/ml; gentamicin, 15 g/ml (for maintenance of B. pertussis and E. coli
strains) or 30 g/ml (for selection of transconjugants); ampicillin, 100 g/ml;
kanamycin, 50 g/ml; streptomycin, 200 g/ml; and tetracycline, 10 g/ml. PCR,
DNA isolation, cloning, and sequencing were performed by standard methods.
Clones were confirmed by sequence analysis, restriction analysis, or Southern
hybridization as appropriate.
Mutagenesis of the risA and risS genes in B. pertussis. The Bordetella pertussis
risAS locus was identified and cloned by our own unpublished analysis and
confirmed through analysis of published sequences (30) and the genomic se-
quence of B. pertussis (49). The genomic sequence data were produced by the B.
pertussis Sequencing Group at the Sanger Centre and were obtained from ftp:
//ftp.sanger.ac.uk/pub/pathogens/bp/. Allelic replacement of an insertionally dis-
rupted risA in BP536 (59) was performed using the allelic exchange vector
pRTP1 (58). Briefly, PCR analysis of a transfected B. pertussis DNA cosmid
library identified one colony whose DNA acted as a template for the amplifica-
tion of risA. The cosmid library was constructed in the vector pHC79 (Boehringer
Ingelheim, Ridgefield, CT) from B. pertussis CN2992 (Wellcome collection)
chromosomal DNA partially digested with Sau3A and transfected into E. coli
XL1-Blue (Stratagene, La Jolla, CA). PCR was performed with primers bpORF
(5-CTGCTGGTTCTCGACCTG-3) and bpORR (5-GGGTTGAAGGGCTT
GGAC-3), which generated a 200-bp risA fragment. The risA-containing cosmid,
pBP2, was digested with SalI-ClaI to release a 1.7-kb DNA fragment which was
cloned into pBluescript II KS() (Stratagene) to create pBP3. A kanamycin
resistance (neo) cassette was inserted at the EcoRI site of the risA fragment in
pBP3 to create pBP15. Insertionally disrupted risA DNA was released as a 3.5-kb
PvuII fragment and cloned into pRTP1 to create pBP16. Triparental matings
were used to mobilize pBP16 from donor E. coli CC118pir (15) into recipient B.
pertussis BP536 using E. coli plasmid-mobilizing helper strain S17-1(pNJ5000)
(12). Double-crossover events were selected on media containing streptomycin
and kanamycin. Southern hybridization using genomic DNA from resultant col-
onies confirmed recombination and mutagenesis. One mutant, BPOR, was cho-
sen for further analysis.
To address the possibility that insertion of the neo gene into risA created
downstream effects on other genes, we created an in-frame deletion of risA by
homologous recombination in B. pertussis. Allelic replacement of the deletion
mutant into BP536 was performed using the allelic exchange vector pSS2141
(42). Briefly, PCR was performed with primers risArev (5-AAGCTTAGCGG
GAAGACGAAGTTTCGAAGGCAA-3) and risAfor (5-CTCGAGGGGGCA
CGAGACGGCGCTCCTG-3), which generated a 948-bp risA-containing frag-
ment. PCR was performed using B. pertussis strain BP338 (64) DNA as the
template. The PCR product was cloned into vector pCR2.1 using the TOPO TA
cloning kit (Invitrogen Life Technologies, Carlsbad, CA) to generate pTS198. A
204-bp in-frame deletion was generated in risA (risA) by restriction digestion
with SstII followed by religation to create pTS210. The risA construct was
cloned as an EcoRI fragment from pTS210 into pSS2141 to generate pTS219.
Triparental matings were used to mobilize pTS219 from donor E. coli DH5
(Invitrogen) into recipient B. pertussis BP536 using E. coli plasmid-mobilizing
helper strain MM294(pRK2013) (20). Integration of the plasmid into the chro-
mosomal copy of risA was selected for by plating on media containing gentami-
cin. A second homologous recombination resulting in the excision of pSS2141
DNA was selected for by plating transconjugates on media containing strepto-
mycin. Isolates were screened for the risA mutant by PCR using the risAfor and
risArev primer pair and template prepared from bacterial colonies (13). The
in-frame risA mutant was confirmed in one clone, BPOR, which was selected
for further analysis.
An in-frame deletion of the risS gene was performed by first amplifying a
2,140-bp fragment of DNA containing the risAS locus by PCR using the primers
risASfor (5-AAGCTTCACCGCCTCATGCGACAC-3) and risASrev (5-AA
GCTTGCCAGCACCGACGAAATGTC-3), which generated flanking HindIII
sites (underlined). The risAS PCR product was cloned into vector pCR2.1 to
generate pTS264. The risAS fragment was then cloned from pTS264 into pUC9
(44) as a HindIII fragment to generate pTS269. A 432-bp in-frame deletion was
generated in risS (risS) by restriction digestion with SstI followed by religation
to create pTS270. The risS-containing fragment was amplified by PCR from
pTS270 using primers risASfor and risASrev and was cloned into vector pCR2.1
to generate pTS272. The risS-containing fragment was then cloned into
pSS2141 from pTS272 as a BamHI fragment to generate pTS273. Allelic re-
placement of risS with risS in B. pertussis strain BP536 was performed using
pTS273 and the mating and selection procedures described for the generation of
the risA mutant. Clones were screened for the risS mutant by PCR using the
risASfor and risASrev primer pair. The in-frame risS mutant was confirmed in
one clone, BPRS, which was selected for further analysis.
A mutant with constitutive expression of the vags and insensitivity to modu-
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TABLE 1. Strains and plasmids
Strain or plasmid Relevant characteristic(s)a Source and/or reference
Strains
B. pertussis
CN2992 B. pertussis wild type Wellcome collection, Kent,
United Kingdom
BP338 Tohama I background; Nalr 64
BP536 Tohama I background; Nalr Strr 59
BPOR BP536, risA::neo; Nalr Strr Kmr This study
BPOR BP536, risA; Nalr Strr This study
BPRS BP536, risS; Nalr Strr This study
BPSC BP536, bvgS-C3; Nalr Strr This study
SCOR BP536, bvgS-C3, risA; Nalr Strr This study
BP-72, -75, -76, -79, -82, and -83 B. pertussis clinical isolates Pertussis Reference Laboratory,
Manchester, United Kingdom
B. parapertussis
CN2951 B. parapertussis human clinical isolate Wellcome collection
BPP-C, -H1, and -K2 B. parapertussis clinical isolates Moredun Institute, Midlothian,
Scotland
B. bronchiseptica
CN7635E B. bronchiseptica wild type Wellcome collection
Bbr-4 to Bbr-9 B. bronchiseptica clinical isolates N. Guiso (26)
E. coli K-12
XL1-Blue High-efficiency transformation Stratagene
One Shot High-efficiency transformation Invitrogen
DH5 High-efficiency transformation Invitrogen
MM294(pRK2013) Conjugation helper strain; carries Kmr mobilizing plasmid;
IncP1 Tra oriE1
20
S17-1(pNJ5000) Conjugation helper strain; carries Tcr mobilizing plasmid;
RP4 Res, Tra, pri, PstIC
12
SM10 Conjugation helper strain; RP4-2Tc::Mu, Kmr 56
CC118pir Lysogenized with pir phage; conjugation-proficient donor 15
Plasmids
pHC79 Cosmid vector; Tcr Apr Boehringer
pUC9 Cloning vector; Apr 44
pBluescript II KS() Cloning vector; Apr Stratagene
pRTP1 Allelic exchange vector for Bordetella pertussis; Apr S. Stibitz (58)
pSS2141 Allelic exchange vector for Bordetella pertussis; Apr Gmr S. Stibitz (42)
pCR2.1 TA cloning vector; Apr Kmr Invitrogen
pFUS2 Integrational vector for generating -Gal fusions; RP4
oriT, Gmr
F. Jacob-Dubuisson (3)
pBP2 B. pertussis risA fragment in cosmid pHC79 This study
pBP3 1.7-kb SalI-ClaI fragment from cosmid clone inserted in
pBluescript II KS(); Apr
This study
pBP15 pBP3 religated with EcoRI-digested 1.3-kb neo fragment;
Apr Kmr
This study
pBP16 3.5-kb PvuII fragment from pBP15 ligated with blunt-
ended pRTP1 vector
This study
pTS198 pCR2.1 containing risA fragment This study
pTS210 pTS198 with SstII deletion of risA This study
pTS219 pSS2141 with EcoRI risA fragment from pTS210 This study
pTS264 pCR2.1 containing risAS fragment This study
pTS269 pUC9 containing HindIII risAS fragment from pTS264 This study
pTS270 pTS269 with SstI deletion of risS This study
pTS272 pCR2.1 containing risAS fragment amplified from pTS269 This study
pTS273 pSS2141 with BamHI risS-containing fragment from
pTS272
This study
pJM503 Allelic exchange vector containing bvgS fragment with
bvgS-C3 mutation
J. Miller (45)
pTS202 pCR2.1 containing kpsM fragment This study
pTS203 pCR2.1 containing vrg-6 fragment This study
pTS206 pFUS2 derivative with bvgR-lacZ fusion This study
pTS208 pFUS2 derivative with kpsM-lacZ fusion This study
pTS209 pFUS2 derivative with vrg-6-lacZ fusion This study
pRK310 Broad-host-range, low-copy-number plasmid; Tcr S. Stibitz (17)
pTS263 pCR2.1 containing risA This study
pRisA pRK310 with HindIII risA from pTS263 This study
a Nalr, naladixic acid resistance; Strr, streptomycin resistance; Gmr, gentamicin resistance; Kmr, kanamycin resistance; Tcr, tetracycline resistance; Apr, ampicillin
resistance.
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lation was generated as a control strain in the analysis of bvg-regulated genes and
phenotypic analysis of the risA mutant BPOR. This was achieved by allelic
exchange of the constitutive bvgS mutant bvgS-C3 into the chromosome of
parental strain BP536 using E. coli SM10(pJM503) (45) as previously described.
Screening for hemolysis identified constitutive bvgS strains that remained hemo-
lytic on BGA containing the modulators 5 mM nicotinic acid and 40 mM MgSO4.
One strain, BPSC, was chosen for further analysis. To assess the affect of a
mutation in risA in a strain with insensitivity to modulation, we constructed B.
pertussis strain SCOR by allelic exchange of risA as described using BPSC as the
parental strain.
Comparisons of the B. pertussis risAS locus with the risAS locus of other
bordetellae was done with genome sequences (49) made available from the
Sanger Centre (these sequence data were produced by the B. bronchiseptica and
B. parapertussis Sequencing Groups at the Sanger Centre and were obtained from
ftp://ftp.sanger.ac.uk/pub/pathogens/bp/, from our own unpublished sequence
data, and by BLAST analysis of published sequences available in the public
databases [GenBank nonredundant nucleotide and protein databases, last ac-
cessed January 2005]).
Complementation of the risA mutant. To confirm that the phenotype de-
scribed in risA bacteria is a result of the disruption of risA only, we constructed
a plasmid containing risA to use for complementation using the low-copy-number
vector pRK310 (17). PCR was performed using primers risASfor (5-AAGCTT
CACCGCCTCATGCGACAC-3) and risACrev (5-AAGCTTAGGCTGACCA
GCATCAGTGC-3) to generate a 1,314-bp piece of DNA with flanking HindIII
sites (underlined). This DNA contains risA starting 438 bp upstream of DNA of
the risA open reading frame and ending 138 bp into the risS open reading frame.
The PCR product was cloned into vector pCR2.1 to generate plasmid pTS263,
which contains the risA gene flanked by BamHI sites. The risA gene was cloned
into pRK310 as a HindIII fragment to create pRisA. Plasmids pRK310 and
pRisA were introduced into B. pertussis strains from E. coli DH5 by triparental
matings using E. coli MM294(pRK2013) and selecting for tetracycline-resistant
B. pertussis.
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis and immunoblot-
ting. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis and immuno-
blotting were performed as previously described (13). Proteins were resolved
using 15% (37.5:1) acrylamide/bis-acrylamide separating gels. The S1 subunit of
pertussis toxin, pertactin, Vra-a, or Vra-a and Vra-b were detected with mono-
clonal antibodies X2X5 (31), BBO5 (11), and 1G7 or monoclonal antibody 7H1
(57), respectively. Peroxidase-conjugated goat anti-mouse immunoglobulin G
(whole-molecule) secondary antibody was purchased from Pierce (Rockford,
IL). Antibody binding was visualized by chemiluminescence using enhanced
chemiluminescence Western blotting detecting reagents (Amersham, Piscat-
away, NJ). Apparent molecular weights were determined by comparison with the
BenchMark prestained molecular weight ladder (Invitrogen).
Construction of transcriptional reporters. -Galactosidase (-Gal) transcrip-
tional reporters were generated using the suicide vector pFUS2 (3) and PCR-
amplified B. pertussis DNA. The following primers were designed to amplify an
internal fragment of bvgR, kpsM, and vrg-6, with flanking HindIII and KpnI
restriction sites (underlined): 5-AAGCTTTGTTCATCCAGCCAGAGCCC-3
(bvgRF) and 5-GGTACCCATGGTCGCCCAGCAGATACC-3 (bvgRR), 5-
AAGCTTCGTTCTTCCTGTTCAGCCACAC-3 (kpsMF) and 5-GGTACCA
ATAAAGGTGCTCCCACGACTTG-3 (kpsMR), and 5-AAGCTTGCCGGA
CTCATGCTCTCCAGCG-3 (vrg-6F) and 5-GGTACCGCGGTCATAGTGC
CGATGGC-3 (vrg-6R). The sizes of the cloned fragments were 441 bp, 309 bp,
and 234 bp for bvgR, kpsM, and vrg-6, respectively. PCR was performed using B.
pertussis strain BP338 DNA as the template, and the products were cloned into
pCR2.1. The resulting plasmids were digested with HindIII-KpnI and cloned
in-frame with the groES gene of pFUS2, resulting in a transcriptional fusion with
the lacZ gene. These fusion constructs were introduced into the chromosomes of
strains BPOR, BPOR, BPSC, and BPRS and their isogenic parent, BP536,
from E. coli DH5 in matings using E. coli MM294(pRK2013). Gentamicin
selects for insertional duplication mutations in the chromosomal copy of the
genes and creates a -Gal transcriptional reporter under the control of the
chromosomal promoters. Strains containing reporters were maintained under
gentamicin selection to select against potential excision of the plasmids. To
complement the risA mutant, pRisA (or control pRK310) was mated into
BPOR reporter strains from DH5 in matings using E. coli MM294(pRK2013).
Unique clones were generated for each transcription assay.
-Galactosidase assay. Transcriptional analysis was done using bacteria grown
on solid media as described previously (3). Transcription was monitored using
-Gal as a reporter using a standard colorimetric assay (40). Data were collected
from four independent assays. Student’s t test was used to analyze the data.
HeLa cell adherence assay. The HeLa cell adherence assay was performed as
a modification of the B. pertussis HeLa cell invasion assay (see below). Bacteria
were incubated with HeLa cell monolayers for 90 min in Eagle minimal essential
medium (MEM; Invitrogen) supplemented with 3% fetal bovine serum (FBS;
Flow Laboratories, McLean, VA) at 37°C in 5% CO2. HeLa monolayers were
then washed five times for 5 min each with rotation at 120 rpm at room tem-
perature using 500 l MEM–3% FBS. Monolayers were then rinsed with trypsin
buffer and treated with 0.25% trypsin solution (Invitrogen) to lift the monolayers
and dislodge adherent bacteria. Cells were diluted in MEM–3% FBS and plated
onto BGA in duplicate for determination of total CFU. Data were collected from
three independent assays. Student’s t test was used to analyze the data.
HeLa cell invasion assay. The gentamicin invasion assay was performed as
previously described (19). Separate control experiments demonstrated that the
risA mutant did not result in an appreciably greater sensitivity to gentamicin than
in parental strains containing wild-type risA (data not shown). Colony counts
were collected from at least three independent assays. Student’s t test was used
to analyze the data.
RESULTS
Sequence analysis of the risAS locus of B. pertussis. The
ompR/envZ orthologs risA and risS were compared between
Bordetella spp. using the published genome sequences of B.
pertussis, B. parapertussis, and B. bronchiseptica; published ri-
sAS gene sequences; and our own sequence analysis. The DNA
sequences of risAS are nearly identical, with a few, mostly
conservative, nucleotide changes between alleles (30). The
strains studied were B. bronchiseptica BB7866, B. pertussis To-
hama I, B. parapertussis 15311 and ML/180, and B. avium
35086. The genomic sequences of B. pertussis Tohama I, B.
parapertussis 12822, and B. bronchiseptica RB50 also reveal
fundamentally identical risAS alleles, with the notable excep-
tion of B. pertussis Tohama I (49). The Tohama I risAS se-
quence differs by only a few bases but most notably contains an
additional C at position 1848. This is within the coding region
of risS and introduces a frameshift in the risS gene. This results
in a downstream opal stop codon and a deduced RisS protein
that is truncated at residue 323 with a predicted molecular
mass of 36 kDa instead of the 52 kDa predicted for the RisS
protein of the other bordetellae. EnvZ of Xenorhabdus nema-
tophilus is only 342 amino acids long but can complement E.
coli envZ-null mutants in an osmodependent manner; however
it is truncated in its N-terminal perplasmic region and still
contains all of the domains important for signal transduction
(61). In contrast, B. pertussis RisS is predicted to lack an EnvZ-
like transmitter domain, which includes the autophosphoryla-
tion site as well as other invariant amino acids and conserved
domains. It is thus highly unlikely that the EnvZ ortholog RisS
is functional as an environmental sensor in B. pertussis. The
domain structures of EnvZ and RisS variants are illustrated in
Fig. 1.
It is possible that this single base change is peculiar to the
strains examined. We therefore used PCR to amplify risS from
other Bordetella isolates and performed sequence analysis to
compare risS alleles. The strains tested were CN2992 and six
clinical isolates from the United Kingdom Pertussis Reference
Laboratory which had been passaged in vitro a maximum of
two times: BP-K72, BP-K75, BP-K76, BP-K79, BP-K82, and
BP-K83. All of these strains contained the extra cytosine re-
sulting in the frameshift mutation in risS. Control strains of B.
parapertussis (CN2591 and three ovine strains, BPP-HI,
BPP-C, and BPP-k2) and B. bronchiseptica (CN 7635E and six
rabbit isolates, BBr-4 through BBr-9) did not contain the
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frameshift mutation and had a full-length risS gene. Hence,
this mutation appears to be common in B. pertussis strains but
rare or absent in B. parapertussis and B. bronchiseptica.
The risA gene is upstream of risS, and the two genes are
separated by only 4 bp, as found in ompR-envZ systems. They
are cotranscribed in B. bronchiseptica (30). The deduced B.
pertussis RisA protein comprises 244 amino acid residues with
a molecular mass of 27.8 kDa and shares a 65.7% identity with
the E. coli OmpR protein. This response regulator family of
proteins is defined by a conserved domain of approximately
100 amino acids that extends over the N terminus of each of
these proteins. In particular, the residues that correspond to
D12, D55, and K105 in the E. coli OmpR protein tend to be
conserved among the response regulator protein family. These
are found at amino acid positions D17, D60, and K110 in the
deduced B. pertussis RisA. Residue D60 of RisA lies in a
domain between V58 and R76 that is completely conserved
between B. pertussis RisA and E. coli OmpR and is likely to be
the site of RisA phosphorylation. In addition, the region be-
tween P83 and I121 that accommodates the invariant K110 is
almost completely conserved between the two proteins (30).
Expression of Bvg-regulated proteins. We have previously
noted that two B. pertussis Vras are not expressed in a risA
transposon mutant (our unpublished observations). Further-
more, mutation of the risAS locus is known to have pleiotropic
effects on B. bronchiseptica gene expression (30). We thus
analyzed protein expression in risAS mutants to investigate
their patterns of Bvg-regulated protein expression. Blots were
probed for expression of the Bvg-activated proteins pertussis
toxin and pertactin and the Bvg-repressed antigens Vra-a (Fig.
2 and Fig. 3, lower-molecular-mass bands) and Vra-b under
both nonmodulating and modulating conditions. B. pertussis
strain BPOR, which has risA insertionally disrupted by a neo
cassette, demonstrated decreased expression of the Vras even
when the bacteria were grown under modulating conditions
but did not appear to have altered expression of the vag prod-
ucts pertactin (Prn) or pertussis toxin subunit S1 (data not
shown). To confirm that the decrease in expression of the Vras
was due specifically to the mutation in risA and not polar
effects due to the neo insertion, we constructed mutants with
single in-frame deletions in risA (BPOR) or risS (BPRS).
Levels of Vra-a and Vra-b were greatly diminished in the risA
mutant compared to the wild type under both nonmodulating
and modulating conditions, while the overall expression of the
Vras was still increased under modulating versus nonmodulat-
ing conditions (Fig. 2, lanes 1 through 4). In contrast, the risS
mutant did not show any alteration in the expression of the
Vras compared to the wild type (Fig. 2, lanes, 1 and 2 and 5 and
6).
To ensure that mutation of risA was specifically responsible
for the decreased expression of the Vras, we introduced either
low-copy-number control vector pRK310 (17) or this vector
containing the wild-type risA gene (pRisA) into the risA mu-
tant BPOR and then analyzed the plasmid-containing strains
in complementation experiments. In addition, we constructed
and analyzed an isogenic mutant containing the bvgS-C3 mu-
tant (BPSC) (45), which has a Bvg-constitutive phenotype, to
act as a Bvg-activated phenotypic control. Immunoblots were
probed for pertussis toxin (subunit S1) and pertactin and the
Bvg-repressed antigens Vra-a and Vra-b (Fig. 3). Pertussis
toxin and pertactin were expressed only in the absence of
modulators in the wild-type strain and risA mutant regardless
of the presence of pRK310 or pRisA, and their expression
levels did not differ appreciably between the risA stains and
their wild-type isogenic parent (Fig. 3A and B). In addition,
standard zones of hemolysis were observed when risA mutants
FIG. 1. Comparison of domain structures of EnvZ and RisS proteins. (A) E. coli EnvZ; (B) Xenorhabdus nematophilus AN6/1 EnvZ; (C) B.
bronchiseptica RB50 RisS; (D) B. pertussis Tohama I RisS. HAMP, receptor histidine kinase domain; HisKA, dimerization/phosphoacceptor,
HATPase_c; histidine kinase-like ATPases.
FIG. 2. Expression of Bvg-repressed antigens in risA and risS mu-
tants. Lanes: 1, parental Bordetella pertussis strain BP536 grown on
BGA without modulators; 2, B. pertussis strain BP536 grown on BGA
with the modulators 5 mM nicotinic acid and 40 mM MgSO4; 3, risA
mutant (BPOR) grown on BGA; 4, risA mutant grown on BGA with
modulators; 5, risS mutant (BPRS) grown on BGA; 6, risS mutant
grown on BGA with modulators. Relative protein levels were assessed
by Western blotting as described in Materials and Methods. (A) Vra-a
(VraA); (B) Vra-b (VraB). Migrations of molecular weight (MW)
markers are indicated on the right.
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were grown on blood agar (data not shown), indicating normal
levels of the vag-encoded bifunctional adenylate cyclase-hemo-
lysin. As expected, the Bvg-constitutive mutant BPSC consti-
tutively expressed pertussis toxin, pertactin, and the hemolytic
phenotype regardless of the presence of modulators. Con-
versely, Vra-a and Vra-b were highly induced under modulat-
ing conditions in wild-type bacteria but were constitutively
repressed in BPSC under the conditions tested (Fig. 3C and
D).
Expression of these Bvg-repressed products was greatly di-
minished in the risA mutant compared to the wild type even
in the presence of modulators, with levels of the Vras in the
modulated risA mutant comparable to nonmodulated levels
in the wild-type strain. Introduction of vector control pRK310
did not restore wild-type expression levels of the Vras under
either nonmodulating or modulating conditions (Fig. 3). How-
ever, introduction of pRisA complemented the risA mutant,
restoring strong expression of the Vras to a level severalfold
higher than that produced by the wild-type strain in the pres-
ence of modulators (Fig. 3C, lane 10). These data indicate that
risA appears to be required for the expression of Bvg-repressed
products, perhaps in a specific manner that does not affect the
expression of Bvg-activated products. In addition, the in-
creased copy number of risA when supplied even on a low-
copy-number plasmid appears to augment expression of the
Vras, suggesting that increasing levels of the RisA activator
may increase expression of the Bvg-repressed antigens.
Transcriptional analysis of Bvg-regulated genes. To deter-
mine if the reduction of expression of Bvg-repressed products
in a risA background was due to reduced transcription, we
analyzed insertional lacZ fusion reporters (Table 2). As ex-
pected, transcription of the Bvg-repressed genes kpsM (which
is predicted to encode a capsule transport protein) (3, 29) and
vrg-6 (which is predicted to encode a small protein of unknown
function) (7) were greatly increased under modulating condi-
tions in the wild-type strain, while their transcription was con-
stitutively repressed in BPSC. Transcription of these vrgs was
greatly reduced in the risA mutant BPOR, even under mod-
ulating conditions. However, introduction of pRisA restored
transcription of the vrgs to a level that was about double that of
the wild type. In contrast, the Bvg-activated gene bvgR was
transcribed at a much higher level under nonmodulating con-
ditions than under modulating conditions in wild-type bacteria,
while it had constitutively high transcription in the control
strain BPSC. As in the wild type, transcription of bvgR was still
high under nonmodulating conditions in the risA mutant and
again was greatly reduced in the presence of modulators. In-
troduction of pRisA did not affect the expression of bvgR in
any of the strains tested.
To test the statistical significance of the transcriptional fu-
sion data, Student’s t test was used. When wild-type BP536 and
the risA mutant BPOR were compared under modulating
conditions, transcription of the vrgs kspM and vrg-6 was signif-
icantly decreased in BPOR (P	 0.01), demonstrating that vrg
transcription is significantly lower when risA is mutated. Tran-
scription of the vag bvgR was not significantly different between
the wild-type bacteria and the risA mutant, confirming that risA
has no apparent role in the transcription of the vags. Analysis
of transcription data for pRisA-complemented risA mutants
demonstrated significantly increased transcription of vrg-6 un-
der both modulating and nonmodulating conditions (P 	
0.01). Significantly increased transcription of kpsM after pRisA
complementation was seen only under modulating conditions;
however, kspM transcription was very low under nonmodulat-
ing conditions and near the limit of detection for the assay
used. These data strongly suggest that the presence of multiple
copies of risA significantly increases transcription of the vrgs
regardless of the affect of Bvg regulation. In summary, these
data indicate that mutation of risA greatly diminishes the ex-
FIG. 3. Expression of Bvg-regulated proteins. Lanes: 1, parental
Bordetella pertussis strain BP536 grown on BGA without modulators; 2,
B. pertussis strain BP536 grown on BGA with the modulators 5 mM
nicotinic acid and 40 mM MgSO4; 3, bvgS-C (BPSC) mutant grown on
BGA; 4, bvgS-C mutant grown on BGA with modulators; 5, risA
mutant (BPOR) grown on BGA; 6, risA mutant grown on BGA with
modulators; 7, risA mutant with low-copy-number vector [BPOR
(pRK310)] grown on BGA; 8, BPOR(pRK310) grown on BGA
with modulators; 9, risA mutant with complementing risA plasmid
[BPOR(pRisA)] grown on BGA; 10, BPOR(pRisA) grown on BGA
with modulators. Relative protein levels were assessed by Western
blotting as described in Materials and Methods. (A) pertactin (Prn);
(B) the S1 subunit of pertussis toxin (S1); (C) Vra-a (VraA); (D) Vra-b
(VraB). Migrations of molecular weight (MW) markers are indicated
on the right.
TABLE 2. -Galactosidase activities of B. pertussis pFus2 integrants
Gene
-Galactosidase unitsa
BP536 (wild type) BPSC (bvgS-C) BPOR (risA) BPOR(pRisA)
NMb SO4-Nicc NM SO4-Nic NM SO4-Nic NM SO4-Nic
bvgR 1,801 
 93 128 
 42 1,700 
 152 2,527 
 165 1,479 
 54 110 
 10 1,545 
 39 24 
 5
kpsM 77 
 5 350 
 52 80 
 13 102 
 33 82 
 18 104 
 26 0 
 2 807 
 62
vrg-6 337 
 24 2,312 
 66 245 
 52 607 
 85 90 
 14 124 
 32 911 
 51 4,354 
 308
a Relative transcription levels were determined by measuring -galactosidase activities from lacZ transcriptional fusions as described in Materials and Methods.
Values are reported as means 
 the standard errors of the means from four independent assays.
b Strains grown on BGA with no modulators (NM).
c Strains grown on BGA with the modulators 5 mM nicotinic acid and 40 mM MgSO4.
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pression of Bvg-repressed products at the level of transcrip-
tion, while not apparently affecting the transcription of the
vags.
Analysis of risA mutants for adherence and invasion in
HeLa cell models. Transcription of risA occurs when B. bron-
chiseptica is inside eukaryotic cells, and risA mutants have
reduced ability to survive within these cells (30, 65). We tested
B. pertussis risA mutant BPOR, the constitutive mutant BPSC,
and their isogenic wild-type parent for adherence to, and sur-
vival in, HeLa cells (Fig. 4).
A reduction in survival in the HeLa cell invasion assay could
be due to reduced adherence, invasion, or survival. To distin-
guish between reduced adherence and reduced invasion or
intracellular survival, we performed an adherence assay using
HeLa cells. After 90-min incubation and washing to remove
nonadherent bacteria, there was no difference in adherence to
HeLa cell monolayers between BPOR and BPSC (P  0.1)
relative to the wild-type control (Fig. 4A).
The invasion of wild-type bacteria and BPSC was not signif-
icantly different (P  0.1). However, there was approximately
fivefold less survival of BPOR relative to the wild type (P 	
0.01) (Fig. 4B). The total numbers of invasive wild-type B.
pertussis were in close agreement with those previously pub-
lished (19), and the strains tested did not have any appreciable
differences in sensitivity to gentamicin (data not shown).
Analysis of Bvg-constitutive mutants in the HeLa cell inva-
sion model. The fact that BPSC and wild-type bacteria survived
equally well suggests that the reduction in survival of the risA
mutant is not due to the diminished expression of Bvg-re-
pressed molecules. We therefore constructed a BvgS-constitu-
tive-risA double mutant and tested it for survival in the HeLa
cell invasion assay to determine if risA mutation affected sur-
vival in the Bvg-constitutive background. The risA mutant
BPOR and the BvgS-constitutive/risA double mutant SCOR
both survived less well than the wild type in the HeLa cell
invasion assay (Fig. 5) (P 	 0.01), even though the Bvg-con-
stitutive strain BPSC did not differ in its survival capability in
the assay (P  0.1). Interestingly, SCOR survived better than
BPOR (P 	 0.01), suggesting that an element of the de-
creased survival in risA mutants may be due to alteration in the
expression of factors not regulated by Bvg.
DISCUSSION
The BvgAS two-component regulatory system is at the apex
in the hierarchical control of virulence factor expression re-
quired for the pathogenesis of the bordetellae. However, in
other pathogens, multiple regulatory networks contribute to
virulence and this is likely to be the case here, too. The OmpR/
EnvZ ortholog RisAS is the second two-component regulatory
system to be described in the bordetellae through experimen-
tation with B. bronchiseptica strains (30, 65). In particular,
ris-dependent products have been implicated in resistance
within macrophages to acid and oxidative stresses by B. bron-
chiseptica (30, 65) and ris is required for bacterial persistence
in a mouse model of infection (65). Expression of ris is bvg
independent, and mutation of ris produces pleiotropic effects
on protein expression. We investigated potential roles for the
RisAS system of B. pertussis in the regulation of virulence,
using risAS mutants.
Our results suggest that RisA is required for the expression
of Bvg-repressed products in B. pertussis. Vra-a and Vra-b are
surface-exposed proteins that are tightly regulated by the
BvgAS system in B. pertussis (43, 57). Mutation of risA results
in greatly decreased expression of Vra-a and Vra-b with levels
produced by modulated risA mutants only about as high as
those produced by unmodulated wild-type B. pertussis. How-
ever, Vra-a and Vra-b were still induced by modulation, sug-
FIG. 4. HeLa cell adherence or invasion by a risA mutant. (A) ad-
herence assay; (B) invasion assay. BP536, parental B. pertussis strain;
BPSC, bvgS-C mutant; BPOR, risA mutant. Values represent 103 CFU
recovered from gentamicin-treated (panel B only) and washed mono-
layers. Error bars represent standard errors of the means for three
replicates. , P 	 0.01, compared to BP536.
FIG. 5. HeLa cell invasion by Bvg-constitutive strains. BP536, pa-
rental B. pertussis strain; BPSC, bvgS-C mutant; BPOR, risA mu-
tant; SCOR; bvgS-C/risA double mutant. Values represent 103 CFU
recovered from gentamicin-treated and washed monolayers. Error
bars represent standard errors of the means for four replicates. , P 	
0.01, compared to BP536.
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gesting that their expression is still repressed by the BvgASR
regulatory cascade but that a functional risA gene is required
for high-level expression of the Vras. Complementation of the
risA mutant with risA on a low-copy-number plasmid restored
the high-level, BvgAS-regulated expression of the Vras to a
level a severalfold higher than that found in wild-type B. per-
tussis. This suggests that an increased level of RisA transacti-
vator increases expression of the Vras.
Transcriptional analysis using gene fusions demonstrated a
dependence on risA for transcription of the vrgs. Transcription
of vrg-6 and kpsM is virtually absent when risA is disrupted.
When risA is supplied in trans, the levels of vrg expression in
modulated bacteria are about twice those of modulated wild-
type bacteria. These results suggest that risA affects vrg expres-
sion and Vra production at the level of transcription. Further-
more, the increased expression of these Bvg-repressed
molecules as a result of there being multiple copies of risA
suggests that increasing concentrations of the RisA transacti-
vator induces higher levels of expression of the vrgs. It will be
interesting to determine whether RisA acts directly to bind the
cis-activating sites of the vrgs or indirectly by altering the ex-
pression of other regulatory molecules.
The Bvg-activated products appear not to be dependent on
RisA for expression, as evidenced by equivalent levels of he-
molysis on blood agar (a result of adenylate cyclase produc-
tion) and comparable levels of pertussis toxin and pertactin
expression between the wild type and risA mutants under non-
modulating conditions. Similarly, ectopic or unregulated pro-
duction of Bvg-regulated products was not observed in risA
mutants. For instance, bvgR has a normal bvg-activated tran-
scription pattern when risA is mutated and pertussis toxin and
pertactin are also not detected under nonmodulating condi-
tions. Thus, it would seem that RisA could play a specific
function in gene regulation as an activator of expression of the
vrgs. However, it will be important to look at an expanded set
of genes and proteins, though genomic and proteomic tech-
niques, to address the likelihood that RisA affects genes other
than just the vrgs.
It is perhaps surprising that a phenotype was detected in B.
pertussis risA mutants, considering that the gene encoding the
cognate sensor RisS is a pseudogene. All the B. pertussis strains
tested have the frameshift mutation in risS, which would result
in a prematurely truncated RisS sensor lacking an EnvZ-like
transmitter domain, and the putative site of RisS autophos-
phorylation. This mutation was not found in risS of B. bron-
chiseptica or B. parapertussis. When B. pertussis risS was mu-
tated to contain a large deletion upstream of the frameshift, it
resulted in no obvious phenotypic effect on gene expression.
Thus, maximal expression of Bvg-repressed products is depen-
dent on functional risA but is independent of risS. It is inter-
esting to speculate that RisA of B. pertussis may be activated by
phosphorylation by a kinase other than RisS via cross talk
between regulatory systems. Interestingly, heterologous phos-
photransfer has been demonstrated between the purified com-
ponents of two-component regulatory systems in vitro (48). In
addition, phosphorylation of OmpR has been observed in
envZ-null mutants of E. coli, suggesting that OmpR can be
phosphorylated by a kinase that is functionally homologous to
EnvZ (21). Cross-regulation has been observed in vivo be-
tween the AcrB sensor of anaerobiosis and the OmpR regula-
tor of porin expression in E. coli, suggesting interplay between
phosphorelay systems (37). Therefore, it is possible that an-
other regulatory system, other than BvgAS or RisAS, may
regulate the expression of the vrgs in B. pertussis via RisA
activation.
B. bronchiseptica risAS expression is maximal at 37°C in the
absence of magnesium cations, when the bacteria are intracel-
lular (30). It will be important to determine which signals
regulate RisA expression and activation in B. pertussis. This is
of particular interest given that risS is a pseudogene in B.
pertussis. It would not be surprising if RisA were to be activated
by different regulatory sensors in B. pertussis and thus also
different environmental signals. It will be interesting to deter-
mine if shuttling a wild-type B. bronchiseptica risS gene to B.
pertussis alters the expression patterns of Bvg-repressed mole-
cules in response to the presence of particular environmental
signals.
It is apparent that the Bvg-repressed arm of the Bvg regulon
has diverged during evolution of the subspecies of the B. bron-
chiseptica cluster (55). B. pertussis in particular expresses a
more limited, but somewhat distinct, set of Bvg-repressed
products compared to B. bronchiseptica. In addition, the re-
quirement for RisA in B. pertussis for maximal expression of
the vrgs contrasts with the pleiotropic nature of the Ris-regu-
lated products in B. bronchiseptica wherein ris is required for
expression of the B. bronchiseptica-specific acid phosphatase,
but not bvg-repressed motility or urease (30). Our results in-
dicate that the genes regulated by risAS and the mechanisms of
RisA-mediated gene regulation have diverged during evolu-
tion of the bordetellae. It is possible that differences in risA
gene regulation and differences in vrg expression in the borde-
tellae have resulted from the same selective pressure that re-
sulted in the evolution of Bordetella subspecies with different
host ranges, physiology, and disease presentations.
B. bronchiseptica ris mutants have reduced survival in mac-
rophage invasion models (30, 65). B. pertussis can invade epi-
thelial-like cells, and the expression of the Bvg-activated phase
is required for adhesion and invasion in these models (6, 19).
Our results in the HeLa cell model suggest that B. pertussis
invasion is risA dependent, while adherence is risA indepen-
dent. Since vrg expression is greatly diminished in risA mutants,
it could be hypothesized that the vrgs are required for this
intracellular survival or invasion. However, we found that Bvg-
activated phase-locked bacteria, which constitutively repress
the vrgs, are as able as wild-type bacteria to survive in HeLa
cells. This suggests that the observed phenotype is probably
due to effects on other genes that are dependent on risA for
expression but that are not Bvg repressed and argues against
modulation of the bacteria to affect increased survival in this
model system. Although risA mutants of B. pertussis enter or
survive less well in HeLa cells, the relevance of epithelial cell
invasion by B. pertussis to the disease state is uncertain, as an
intracellular niche has not been demonstrated for this bacte-
rium. It is possible that invasion occurs in low numbers in
humans in a location in which the bacteria are hard to detect.
Alternatively, the readout in the invasion models could reflect
another biologically relevant aspect of B. pertussis ecology,
even if the bacterium does not invade eukaryotic cells in vivo,
and it is conceivable that RisA has a biologically important
function in B. pertussis in vivo through an influence on the
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expression of vrgs or other genes. Further work will be required
to determine if the HeLa cell invasion data reflect a biologi-
cally relevant interaction of the bacterium with host cells or if
they reflect a more general phenotype related to the ability of
B. pertussis to survive stressful factors in its environment.
In B. bronchiseptica, biologically relevant phenotypes have
been attributed to vrg-encoded products such as motility for
flagella (1, 2) and urea degradation for urease (39). In B.
pertussis, a relevant vrg-encoded biological phenotype is uncer-
tain. Although a Bvg-repressed capsule has not been described
for B. pertussis, kpsM, a capsule biosynthesis gene, has been
described as a vrg in B. pertussis (3, 29). This is intriguing, as
polysaccharide capsules are known to be important virulence
factors for a number of bacteria (47). We have confirmed that
kpsM is a B. pertussis vrg; however, it is unknown whether the
KpsM protein is expressed in B. pertussis. Furthermore, in B.
pertussis, several other genes of the capsule biosynthesis locus
have been inactivated or have been shuttled to alternate posi-
tions in the chromosome (49). It is possible that the altered
subset of capsule synthesis genes could have a biological func-
tion in B. pertussis.
The smaller number of vrgs expressed in B. pertussis com-
pared with B. bronchiseptica may indicate that the B. pertussis
vrgs are decaying relative to B. bronchiseptica. However, many
vrgs are still expressed in B. pertussis, and moreover, the ex-
pression patterns of the vrgs differ between the two subspecies.
It is hoped that further investigation of Ris- and Bvg-mediated
regulation will elucidate a role (either current or ancestral) for
both ris and the vrgs in the life cycle of the human pathogen B.
pertussis.
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